Crossmark

Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor

Crossref DOI link: https://doi.org/10.1007/s40268-020-00314-3

Published Online: 2020-07-02

Published Print: 2020-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Monestime, Shanada https://orcid.org/0000-0002-5994-065X
Lazaridis, Dovena https://orcid.org/0000-0001-5075-8176
License Information

Text and Data Mining valid from 2020-07-02

Version of Record valid from 2020-07-02
More Information

Article History

First Online: 2 July 2020

Compliance with Ethical Standards

:

: This study was not funded.

: The authors declare that they have no conflict of interest.